David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RDUS
2626
CALL
DELISTED
Radius Health, Inc.
RDUS
| $881K | ﹤0.01% |
44,200
| – | – |
|
|
CCRN
2627
DELISTED
Cross Country Healthcare
CCRN
| $880K | ﹤0.01% |
125,165
+11,046
| +10% | +$94.7K |
|
2628
PUT
HF Sinclair
DINO
$17.2B
| $877K | ﹤0.01% |
17,800
-60,700
| -77% | -$3.23M |
|
2629
CALL
Rockwell Automation
ROK
$47.9B
| $877K | ﹤0.01% |
5,000
-45,000
| -90% | -$7.65M |
|
2630
Acushnet Holdings
GOLF
$5.07B
| $876K | ﹤0.01% |
37,829
-34,078
| -47% | -$797K |
|
2631
Dime Commercial Bancshares
DCOM
$1.78B
| $875K | ﹤0.01% |
29,842
+5,484
| +23% | +$166K |
|
|
UMH
2632
UMH Properties
UMH
$1.42B
| $875K | ﹤0.01% |
62,138
-19,277
| -24% | -$259K |
|
|
MANT
2633
DELISTED
Mantech International Corp
MANT
| $874K | ﹤0.01% |
+16,188
| New | +$887K |
|
2634
Plug Power
PLUG
$3.03B
| $873K | ﹤0.01% |
363,572
-1,419,572
| -80% | -$2.48M |
|
2635
PUT
Carvana
CVNA
$81.3B
| $871K | ﹤0.01% |
75,000
-39,500
| -34% | -$332K |
|
2636
CALL
C.H. Robinson
CHRW
$17.7B
| $870K | ﹤0.01% |
10,000
-5,000
| -33% | -$439K |
|
2637
Core Laboratories
CLB
$550M
| $870K | ﹤0.01% |
12,624
-39,465
| -76% | -$2.65M |
|
|
MNK
2638
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $870K | ﹤0.01% |
40,000
-3,500
| -8% | -$74.6K |
|
2639
PUT
Incyte
INCY
$26B
| $869K | ﹤0.01% |
10,100
-118,000
| -92% | -$9.6M |
|
2640
Invitation Homes
INVH
$17.8B
| $868K | ﹤0.01% |
+35,691
| New | +$803K |
|
2641
Ball Corp
BALL
$17B
| $867K | ﹤0.01% |
+14,992
| New | +$799K |
|
2642
CALL
NewMarket
NEU
$8.51B
| $867K | ﹤0.01% |
2,000
-5,000
| -71% | -$2.11M |
|
|
ALLK
2643
DELISTED
Allakos
ALLK
| $865K | ﹤0.01% |
+21,352
| New | +$863K |
|
2644
CALL
Sun Communities
SUI
$15.3B
| $865K | ﹤0.01% |
+7,300
| New | +$812K |
|
2645
PUT
Everest Group
EG
$14.6B
| $864K | ﹤0.01% |
4,000
-11,900
| -75% | -$2.59M |
|
|
GRMN
2646
PUT
Garmin
GRMN
$55.7B
| $864K | ﹤0.01% |
+10,000
| New | +$753K |
|
2647
Minerva Neurosciences
NERV
$259M
| $860K | ﹤0.01% |
13,675
+2,276
| +20% | +$137K |
|
|
PRFT
2648
DELISTED
Perficient Inc
PRFT
| $860K | ﹤0.01% |
31,405
-59,594
| -65% | -$1.57M |
|
|
SGMO
2649
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $859K | ﹤0.01% |
90,000
| – | – |
|
|
CRHM
2650
DELISTED
CRH Medical Corporation
CRHM
| $858K | ﹤0.01% |
324,600
+400
| +0.1% | +$1.24K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.